<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02781337</url>
  </required_header>
  <id_info>
    <org_study_id>1513</org_study_id>
    <secondary_id>REM-CCR</secondary_id>
    <nct_id>NCT02781337</nct_id>
  </id_info>
  <brief_title>Epidemiological and Molecular Colorectal Cancer Registry</brief_title>
  <acronym>EMR-CRC</acronym>
  <official_title>Epidemiological and Molecular Colorectal Cancer Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Italiano de Buenos Aires</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Italiano de Buenos Aires</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Registry that invites patients undergoing colorectal surgery for colorectal cancer.
      Epidemiological data is collected. The Registry includes tumor tissue and blood banks for
      analyzing different genetic mutations and disease-specific biomarkers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Registry that invites patients undergoing colorectal surgery for colorectal cancer.
      Epidemiological data is collected. The Registry includes tumor tissue and blood samples banks
      used to studied different genetic variants and disease-specific biomarkers present in
      patients with Lynch syndrome and others hereditary cancers.

      The aim of this registry is to set up the necessary resources to help basic and clinical
      research projects on colorectal cancer (CRC) within the Hospital Italiano de Buenos Aires
      (HIBA) and promote scientific collaborations between the HIBA and other institutions within
      and outside the country.

      To make this project, the following specific goals are proposed:

      Objective 1: Establishment of an efficient algorithm to enroll patients diagnosed with CRC
      from HIBA, through collaboration between the services of Surgery, Gastroenterology,
      Pathology, Oncology, Institute of Translational Medicine and Biomedical Engineering (IMTIB),
      Medical Clinic and Medical Informatics.

      Objective 2: Development of logistics for the connection and expansion of the bank of
      biological samples (DNA, serum) and tumor samples (tissue fixed in formalin, frozen tissue)
      to the CRC.

      Objective 3: Development of computer software to record data about patient enrolled in a
      dynamic way.

      Objective 4: Development of pipelines and create a supervisory committee to regulate the
      future of samples and data obtained through the registry, accord the current standards of
      ethical code, and improve the current collaborations with foreign researchers.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Anticipated">December 2033</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>10 Years</target_duration>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years</time_frame>
    <description>Patient overall survival at 5 years.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>5 years</time_frame>
    <description>The time free of disease recurrence will be estimated in the whole cohort and according to colorectal cancer stages and molecular profiles.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Molecular characteristics of colorectal adenocarcinoma.</measure>
    <time_frame>0</time_frame>
    <description>At initial diagnosis, molecular tumor markers will be determined in the tissue samples.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">2100</enrollment>
  <condition>Colorectal Neoplasms</condition>
  <condition>Colorectal Cancer</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Tissue samples and blood specimens are frozen and store at Eighty degrees below 0 degrees
      Celsius (-80ºC).
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients undergoing colorectal surgery due to colorectal cancer.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients undergoing colorectal surgery for colorectal cancer.

        Exclusion Criteria:

          -  Unwillingness to participate.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>96 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carlos Vaccaro, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Italiano de Buenos Aires</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Carlos Vaccaro, MD</last_name>
    <email>carlos.vaccaro@hospitalitaliano.org.ar</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>María L González, MD</last_name>
    <email>marialaura.gonzalez@hospitalitaliano.org.ar</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Italiano de Buenos Aires</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aires</state>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>HIBA</last_name>
      <phone>54-11-49590200</phone>
      <phone_ext>8863</phone_ext>
    </contact>
    <investigator>
      <last_name>Carlos Vaccaro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>María L González, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tamara A Piñero, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Argentina</country>
  </location_countries>
  <reference>
    <citation>Collura A, Lagrange A, Svrcek M, Marisa L, Buhard O, Guilloux A, Wanherdrick K, Dorard C, Taieb A, Saget A, Loh M, Soong R, Zeps N, Platell C, Mews A, Iacopetta B, De Thonel A, Seigneuric R, Marcion G, Chapusot C, Lepage C, Bouvier AM, Gaub MP, Milano G, Selves J, Senet P, Delarue P, Arzouk H, Lacoste C, Coquelle A, Bengrine-Lefèvre L, Tournigand C, Lefèvre JH, Parc Y, Biard DS, Fléjou JF, Garrido C, Duval A. Patients with colorectal tumors with microsatellite instability and large deletions in HSP110 T17 have improved response to 5-fluorouracil–based chemotherapy. Gastroenterology. 2014 Feb;146(2):401-11.e1.</citation>
    <PMID>24512910</PMID>
  </reference>
  <reference>
    <citation>Kim JH, Kang GH. Molecular and prognostic heterogeneity of microsatellite-unstable colorectal cancer. World J Gastroenterol. 2014 Apr 21;20(15):4230-43. doi: 10.3748/wjg.v20.i15.4230. Review.</citation>
    <PMID>24764661</PMID>
  </reference>
  <reference>
    <citation>Phipps AI, Limburg PJ, Baron JA, Burnett-Hartman AN, Weisenberger DJ, Laird PW, Sinicrope FA, Rosty C, Buchanan DD, Potter JD, Newcomb PA. Association between molecular subtypes of colorectal cancer and patient survival. Gastroenterology. 2015 Jan;148(1):77-87.e2. doi: 10.1053/j.gastro.2014.09.038. Epub 2014 Sep 30.</citation>
    <PMID>25280443</PMID>
  </reference>
  <reference>
    <citation>Kim JH, Bae JM, Oh HJ, Lee HS, Kang GH. Pathologic Factors Associated with Prognosis after Adjuvant Chemotherapy in Stage II/III Microsatellite-Unstable Colorectal Cancers. J Pathol Transl Med. 2015 Mar;49(2):118-28. doi: 10.4132/jptm.2015.02.05. Epub 2015 Mar 12.</citation>
    <PMID>26148739</PMID>
  </reference>
  <reference>
    <citation>Jenkins MA, Hayashi S, O'Shea AM, Burgart LJ, Smyrk TC, Shimizu D, Waring PM, Ruszkiewicz AR, Pollett AF, Redston M, Barker MA, Baron JA, Casey GR, Dowty JG, Giles GG, Limburg P, Newcomb P, Young JP, Walsh MD, Thibodeau SN, Lindor NM, Lemarchand L, Gallinger S, Haile RW, Potter JD, Hopper JL, Jass JR; Colon Cancer Family Registry. Pathology features in Bethesda guidelines predict colorectal cancer microsatellite instability: a population-based study. Gastroenterology. 2007 Jul;133(1):48-56. Epub 2007 Apr 25.</citation>
    <PMID>17631130</PMID>
  </reference>
  <reference>
    <citation>Webber EM, Kauffman TL, O'Connor E, Goddard KA. Systematic review of the predictive effect of MSI status in colorectal cancer patients undergoing 5FU-based chemotherapy. BMC Cancer. 2015 Mar 21;15:156. doi: 10.1186/s12885-015-1093-4. Review.</citation>
    <PMID>25884995</PMID>
  </reference>
  <reference>
    <citation>Park JG, Kim DW, Hong CW, Nam BH, Shin YK, Hong SH, Kim IJ, Lim SB, Aronson M, Bisgaard ML, Brown GJ, Burn J, Chow E, Conrad P, Douglas F, Dunlop M, Ford J, Greenblatt MS, Heikki J, Heinimann K, Lynch EL, Macrae F, McKinnon WC, Möeslein G, Rossi BM, Rozen P, Schofield L, Vaccaro C, Vasen H, Velthuizen M, Viel A, Wijnen J; International Society for Gastrointestinal Hereditary Tumours. Germ line mutations of mismatch repair genes in hereditary nonpolyposis colorectal cancer patients with small bowel cancer: International Society for Gastrointestinal Hereditary Tumours Collaborative Study. Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3389-93.</citation>
    <PMID>16740762</PMID>
  </reference>
  <reference>
    <citation>Jass JR. Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology. 2007 Jan;50(1):113-30. Review.</citation>
    <PMID>17204026</PMID>
  </reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>May 17, 2016</study_first_submitted>
  <study_first_submitted_qc>May 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 24, 2016</study_first_posted>
  <last_update_submitted>February 14, 2020</last_update_submitted>
  <last_update_submitted_qc>February 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Italiano de Buenos Aires</investigator_affiliation>
    <investigator_full_name>Carlos Vaccaro</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

